BÜHLMANN fCAL® ELISA Citation Walsham and Sherwood. Fecal calprotectin in inflammatory bowel disease, Clinical and Experimental Gastroenterology. 2016; 9: 21–29.Published online 2016 Jan 28. doi: 10.2147/CEG.S51902
Highlight from this Publication
“The choice of a cutoff will depend on whether sensitivity or specificity is considered to be the most important and needs to be made taking into consideration the clinical features of an individual patient.”
BÜHLMANN fCAL®ELISA Citation Pavlidis, P ,Pavlidis P, Chedgy FJ, Tibble JA. Diagnostic accuracy and clinical application of faecal calprotectin in adult patients presenting with gastrointestinal symptoms in primary care, Scandinavian Journal of Gastroenterology. 2013 Sep;48(9):1048-54. doi: 10.3109/00365521.2013.816771.
Highlight from this Publication
“This study provides the first evidence on the use of fCal [BÜHLMANN fCAL® ELISA]testing in primary care…..to be used as part of the pathway for management of patients with suspected IBS.”
BÜHLMANN fCAL® ELISA Citation: Mindemark, M. & Larsson, A. Ruling out IBD: Estimation of the possible economic effects of pre-endoscopic screening with F-calprotectin, Clinical Biochemistry. Clin Biochem. 2012 May;45(7-8):552-5. doi: 10.1016/j.clinbiochem.2011.10.015.
Highlights from this Publication:
“The estimated demand for colonoscopies was reduced by 50% to 67%. This corresponded to a cost avoidance of approximately up toa cost avoidance of approximately up to €2.13 million.”
BÜHLMANN fCAL® ELISA Citation: Jensen, M.D., Kjeldsen J, Nathan T. Fecal calprotectin is equally sensitive in Crohn’s disease affecting the small bowel and colon. Scand J Gastroenterol. 2011 Jun;46(6):694-700. doi: 10.3109/00365521.2011.560680.
Highlights from this Publication:
“The first study to show that fecal calprotectin is equally sensitive in colonic and small bowel CD.”
BUHLMANN Diagnostics Corp
105 Route 101A, Suite 1
Amherst, NH 03031
USA
(844) 300-9799
(603) 732-0675
info@buhlmannlabs.com
